Yale Study Identifies Effective Anti-Aging Treatments

Researchers at Yale have identified that certain prescription medications and lifestyle changes can reduce biological age as measured by DNA-based blood tests, according to a study published in Nature Medicine. The findings suggest that interventions such as metformin and semaglutide, which are used to manage metabolic conditions and body weight, may have significant effects on slowing biological aging. This research was conducted in the laboratory of Albert Higgins-Chen, an assistant professor of psychiatry at the Yale School of Medicine, and led by Raghav Sehgal, now an associate research scientist in psychiatry who specializes in computational biology and bioinformatics (source ID: 1). [1]

The study involved an analysis of 51 clinical studies investigating different anti-aging strategies, including dietary supplements, medications, lifestyle changes, and medical procedures. The researchers examined more than 110 DNA methylation biomarkers, including 16 major epigenetic clocks, to evaluate which interventions were associated with reductions in biological age. The results showed that lifestyle modifications, such as regular physical activity combined with healthy eating plans like the Mediterranean, low-fat, or low-carb diets, consistently reduced epigenetic age (source ID: 1). [1]

Prescription medications such as metformin and semaglutide were among the treatments associated with the strongest reductions in biological age. The study also found that anti-TNF therapies, which target a protein involved in the body's inflammatory response, showed promising results. In contrast, over-the-counter supplements and some medical procedures did not produce measurable reductions in epigenetic age. The research team emphasized the importance of using improved DNA-based blood tests to evaluate anti-aging therapies more effectively (source ID: 1). [1]

The research was conducted at Yale University, specifically within the Yale School of Medicine and the Department of Psychiatry. The study was led by Raghav Sehgal, an associate research scientist in psychiatry, and took place in the laboratory of Albert Higgins-Chen, an assistant professor of psychiatry at Yale. The project involved multiple researchers, including Daniel Borrus, Jenel F. Armstrong, John Gonzalez, Jessica Kasamoto, and Yaroslav Markov, all affiliated with the Higgins-Chen laboratory. The research was supported by affiliated programs such as Yale's Department of Pathology, the Computational Biology and Bioinformatics Program, and the Y-Age Yale Center for Research on Aging. [1]